Mergers & Acquisitions ·
Indivior Pharmaceuticals, Inc. announced the execution of a definitive Agreement and Plan of Merger with Supernus…
INDVSupernus, Inc.
Indivior Pharmaceuticals, Inc. announced the execution of a definitive Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc., creating a $2.2 billion diversified central nervous system biopharmaceutical leader through a 100% tax-free stock-for-stock transaction. Under the terms, Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share, resulting in an ownership split of 56.5% for Indivior and 43.5% for Supernus post-close. Prior to closing, Indivior will declare a $1 billion aggregate special cash dividend to pre-closing stockholders, funded by approximately $650 million in additional debt. The combined entity will feature an expanded executive team led by Supernus CEO Jack Khattar and a board with four directors from each company. The transaction targets closing in Q4 2026, subject to shareholder and regulatory approvals, and anticipates at least $125 million in annual cost synergies based on pro forma LTM net revenues of $2.16 billion as of June 30, 2026. Indivior Pharmaceuticals operates in the pharmaceutical industry, specializing in treatments for opioid use disorder.